SAN FRANCISCO: (Oct 30) In a breakthrough for Indian medical innovation, a new generation heart stent developed and manufactured in India has earned global recognition after outperforming a leading US-made stent in high-risk patients.
Presenting the findings at a major international cardiology conference in San Francisco, Dr Upendra Kaul, Chairman and Dean of Delhi’s Batra Hospital, revealed that the Indian-made Supraflex Cruz demonstrated a lower failure rate than the globally dominant Xience stent from the US.
The results stem from the TUXEDO-2 trial, a multi-centre study conducted across 66 cardiology centres in India. The trial specifically focused on high-risk patients, including those with diabetes and advanced multi-vessel disease—conditions that make angioplasty procedures more complex and outcomes harder to improve.
“Over 80 per cent of the participants had triple-vessel disease, making this one of the toughest test groups globally,” said Dr Kaul, who led the trial.
The Supraflex Cruz stent, developed by the Indian company SMT (Sahajanand Medical Technologies), has now joined the ranks of internationally validated devices—a milestone for India’s growing med-tech industry. The findings are expected to boost confidence in Indian-made cardiovascular implants, which are often priced at a fraction of imported alternatives.